Evaluation of Vascular Endothelial Growth Factor, Irisin, Copeptin Levels and Some Biochemical Factors in Patients With Polycystic Ovary Syndrome in Samarra City

Qaisar Mashan Abd

doi:10.61132/obat.v2i6.836

Authors

Qaisar Mashan Abd University of Tikrit

DOI:

https://doi.org/10.61132/obat.v2i6.836

Keywords:

Polycystic ovary syndrome , Vascular endothelial growth factor, Irisin , Copeptin

Abstract

This study was conducted in the laboratories of Samarra Teaching Hospital and some private laboratories in the city of Samarra in salah aldiyn Governorate for a period from 1/8/2024 to 1/9/2024, where the study included (50) samples of women of reproductive age, ranging in age from (20-40) years, and were distributed into two groups: Patient group: (30) samples were from female patients with PCOS, Control group: (20) samples of healthy women. The pathological cases of women suffering from PCOS were confirmed after conducting clinical examinations and referring them to the specialist doctor and performing an ultrasound examination. after that, blood was taken from both groups (patients and healthy women) and separated using a centrifuge. Then the sex hormones Luting hormone -LH, Folic stimulating hormone-FSH, and some biochemical variables, which included (Vascular endothelial growth factor-VEGF , Irisin, Copeptin). The results of the this study showed a significant rise in each of the hormones (LH. FSH, Testosterone ,Copeptin, VEGF) and a significant low in (Irisin) in the blood serum of women infected with PCOS compered a healthy women , with a probability of P ≤ 0.05.

Downloads

Download data is not yet available.

References

Abbas, M. Q., & Sarhat, E. R. (2018). Estimation of the activity of copeptin, insulin, and C-peptide from patients with polycystic ovary syndrome. Tikrit Journal of Pure Science, 23(4), 7–9.

Abdulwahid, H. H., Hussein, B. A., Omran, Z. S., & Alhasanawy, S. A. (2019). Disorders of sex hormones and lipid profile in obese and non-obese women with polycystic ovary syndrome in Karbala City. Annals of Tropical Medicine and Health, 22, 100–106.

Agrawal, R., Jacobs, H., Payne, N., & Conway, G. (2002). Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertility and Sterility, 78(6), 1164–1169.

Agrawal, R., Sladkevicius, P., Engmann, L., Conway, G. S., Payne, N. N., Bekis, J., et al. (1998). Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Human Reproduction, 13(3), 651–655.

Al-Akabi, D. F. (2019). Study of some hormonal and biochemical parameters associated with polycystic ovary syndrome in Basrah (D.Ph. Thesis, College of Education for Pure Sciences, Al-Basrah University).

Al-Bayyari, N., Eaton, A., & et al. (2021). Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo-controlled clinical trial. Clinical Nutrition, 40(3), 870–878. https://doi.org/10.1016/j.clnu.2020.09.024

Brown, J. B. (1978). Pituitary control of ovarian function—concepts derived from gonadotropin therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 18(1), 47–54.

Burtis, C. A., & Ashwood, E. R. (1999). Textbook of clinical chemistry (3rd ed.). W.B. Saunders Company.

Coelho, J. M., D’Cunha, P., & Shivashankara, A. R. (2024). Serum copeptin as a biomarker of polycystic ovarian syndrome and its correlation with metabolic syndrome components: A cross-sectional analytical study. Journal of Clinical and Diagnostic Research, 18(7), QC01-QC04.

Creatsas, G., & Deligeoroglou, E. (2023). Polycystic ovarian syndrome in adolescents. Current Opinion in Obstetrics and Gynecology, 19(5), 420–426.

Dambala, K., Paschou, S. A., Michopoulos, A., Siasos, G., Goulis, D. G., Vavilis, D., et al. (2019). Biomarkers of endothelial dysfunction in women with polycystic ovary syndrome. Angiology, 70(9), 797–801.

Dambala, K., Vavilis, D., Bili, E., Goulis, D. G., & Tarlatzis, B. C. (2017). Serum visfatin, vascular endothelial growth factor, and matrix metalloproteinase-9 in women with polycystic ovary syndrome. Gynecological Endocrinology, 33(7), 529–533.

Ee, S., Pirotta, A., Mousa, L., Moran, S., & Lim, S. (2021). Providing lifestyle advice to women with PCOS: An overview of practical issues affecting success. Unpublished manuscript, 1–12.

Eng, L., Azad, A. K., Habbous, S., Pang, V., Xu, W., Maitland-van der Zee, A. H., et al. (2012). Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A systematic review and meta-analysis. Clinical Cancer Research, 18(17), 4526–4537.

Espes, D., & Carlsson, P. (2015). Increased levels of irisin in people with long-standing type 1 diabetes. Diabetes Medicine, 32(9), 72–76.

Ferrara, N., & Henzel, W. J. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications, 161(2), 851–858.

Ferrara, N., Frantz, G., LeCouter, J., Dillard-Telm, L., Pham, T., Draksharapu, A., et al. (2003). Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. The American Journal of Pathology, 162(6), 1881–1893.

Herman, J. P., Prewitt, C. M., & Cullinan, W. E. (1996). Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Critical Reviews in Neurobiology, 10, 371–394.

Hsu, M. I., Liou, T. H., Liang, S. J., Su, H. W., Wu, C. H., & Hsu, C. S. (2009). Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertility and Sterility, 91(4), 1168–1174. https://doi.org/10.1016/j.fertnstert.2008.01.036

Jaripur, M., Ghasemi-Tehrani, H., Askari, G., Gholizadeh-Moghaddam, M., Clark, C. C. T., & Rouhani, M. H. (2022). The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: A randomized clinical trial. Reproductive Biology and Endocrinology, 20(1), 1–11.

Karbek, B., Ozbek, M., Karakose, M., Topaloglu, O., Bozkurt, N. C., Cakır, E., ... & Delibasi, T. (2014). Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. Journal of Ovarian Research, 7(1), 1–6.

Konieczna, A., Rachoń, D., Owczarek, K., Kubica, P., Kowalewska, A., Kudłak, B., ... & Namieśnik, J. (2018). Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome. Reproductive Toxicology, 82, 32–37.

Li, Y., Fang, L., Yu, Y., Shi, H., Wang, S., Li, Y., Yan, Y., Sun, Y. P. (2020). Association between vascular endothelial growth factor gene polymorphisms and PCOS risk: A meta-analysis. Reproductive BioMedicine Online, 40(2), 287–295.

Louis, V. (2007). Polycystic ovary syndrome (PCOS). U.S. Department of Health and Human Services, Office on Women's Health, 1–6.

Mahdi, H. A., & Al-Samarrai, R. R. H. (2021). Evaluation of the correlation between the level of asprosin and some biochemical parameters in women with polycystic ovary syndrome. Samarra Journal of Pure and Applied Science, 3(2), 12–24.

Martinez Munoz, I. Y., Camarillo Romero, E. D. S., & Garduno Garcia, J. D. J. (2018). Irisin: A novel metabolic biomarker—present knowledge and future directions. International Journal of Endocrinology.

Morgenthaler, N. G. (2010). Copeptin: A biomarker of cardiovascular and renal function. Congestive Heart Failure, 16, S37–S44.

National Institutes of Health. (2022). Polycystic ovary syndrome (PCOS). https://www.nichd.nih.gov/health/topics/factsheets/pcos

Ozen, F. Z., Kaya-Sezginer, E., Kırlangıc, O. F., Tekeli Taskomur, A., Aktan, F., Kaplan, G., & Ozgurtas, T. (2024). Vascular endothelial growth factor (VEGF)-C and its receptors, soluble VEGFR-2 and VEGFR-3, in polycystic ovary syndrome. De Gruyter.

Renner, W., Kotschan, S., Hoffmann, C., Obermayer-Pietsch, B., & Pilger, E. (2000). A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. Journal of Vascular Research, 37(6), 443–448.

S, X., W, X., Z, Y., Y, X., & Z, W. (2015). Evaluation of apelin and insulin resistance in patients with PCOS and therapeutic effect of drospirenone-ethinylestradiol plus metformin. Medical Science Monitor, 21, 2547–2552.

Sarhat, E. R., & Abbas, M. Q. (2018). Estimation of the activity of copeptin, insulin, and C-peptide from patients with polycystic ovary syndrome. Tikrit Journal of Pure Science, 23(4), 7–9.

Shabbir, S., Khurram, E., Moorthi, V. S., et al. (2023). The interplay between androgens and the immune response in polycystic ovary syndrome. Journal of Translational Medicine, 21, 259. https://doi.org/10.1186/s12967-023-04116-4

Taskin, M. I., Bulbul, E., Adali, E., Hismiogulları, A. A., & Inceboz, U. (2015). Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology, 189, 19–23.

Telagareddy, R., Kumar, P. R., Pattanaik, S. R., Dash, D. K., Patro, D., Sahoo, B. K., & Sahu, M. (2024). Serum irisin in polycystic ovary syndrome and its alteration with metformin intervention. Indian Journal of Endocrinology and Metabolism, 28(1), 91–97.

Valdimarsdottir, R., Wikström, A., Kallak, T. K., Elenis, E., Axelsson, O., Preissl, H., Ubhayasekera, S. J. K. A., Bergquist, J., & Poromaa, I. S. (2020). Pregnancy outcome in women with polycystic ovary syndrome in relation to second-trimester testosterone levels. Reproductive BioMedicine Online, 42(1), 217–225.

Wide, L. (1976). Hormone assays and their clinical applications. In L. J. A. Ed & E. T. Bell (Eds.), Human Pituitary Gonadotropins (pp. 87–140). Churchill Livingstone.

Widecka, J., Ozegowska, K., Banaszewska, B., Kazienko, A., Safranow, K., Branecka-Wozniak, D., Pawelczyk, L., & Kurzawa, R. (2019). Is copeptin a new potential biomarker of insulin resistance in polycystic ovary syndrome? Ginekologia Polska, 90(3), 115–121.

Yildiz, N., Calan, M., Cobanoglu, M., Sengul, H. I., Unal Kocabas, G., & Guclu, S. (2016). The association between increased circulating irisin levels and inflammatory markers in polycystic ovary syndrome. Endocrine Abstracts, 41, EP672.

Zhao, J., Li, D., Tang, H., & Tang, L. (2020). Association of vascular endothelial growth factor polymorphisms with polycystic ovarian syndrome risk: A meta-analysis. Published online March 9, 2020.